Matthew Taylor
Stock Analyst at Jefferies
(3.21)
# 1,076
Out of 4,761 analysts
177
Total ratings
59.46%
Success rate
8.73%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $91.09 | +13.07% | 2 | Jan 8, 2025 | |
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $134.92 | -7.35% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $73.30 | -4.50% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $282.80 | -21.15% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $18.90 | +0.53% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $89.94 | -15.50% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $3.55 | +3,421.13% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $169.96 | -28.81% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.72 | +196.61% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $31.00 | +45.16% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.96 | -47.98% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $21.13 | +150.83% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $12.64 | +89.87% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $382.78 | -9.87% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $104.83 | +24.01% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $291.68 | -21.15% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $17.84 | +12.11% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $61.13 | +39.05% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $80.28 | -6.58% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $231.69 | +5.74% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $33.82 | +83.32% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $175.64 | +19.56% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $10.61 | +13.10% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $88.78 | +40.80% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $104.49 | -52.15% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $591.79 | -64.51% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $5.73 | +441.01% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $47.44 | +102.36% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $4.30 | +62.79% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $227.43 | +16.96% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $10.33 | +54.89% | 2 | Jul 19, 2017 |
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $91.09
Upside: +13.07%
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $134.92
Upside: -7.35%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $73.30
Upside: -4.50%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $282.80
Upside: -21.15%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $18.90
Upside: +0.53%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $89.94
Upside: -15.50%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $3.55
Upside: +3,421.13%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $169.96
Upside: -28.81%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.72
Upside: +196.61%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $31.00
Upside: +45.16%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.96
Upside: -47.98%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $21.13
Upside: +150.83%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $12.64
Upside: +89.87%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $382.78
Upside: -9.87%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $104.83
Upside: +24.01%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $291.68
Upside: -21.15%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $17.84
Upside: +12.11%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $61.13
Upside: +39.05%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $80.28
Upside: -6.58%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $231.69
Upside: +5.74%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $33.82
Upside: +83.32%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $175.64
Upside: +19.56%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $10.61
Upside: +13.10%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $88.78
Upside: +40.80%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $104.49
Upside: -52.15%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $591.79
Upside: -64.51%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $5.73
Upside: +441.01%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $47.44
Upside: +102.36%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $4.30
Upside: +62.79%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $227.43
Upside: +16.96%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $10.33
Upside: +54.89%